Archive for the 'Pleural' Category
Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.
November 28th, 2009. Biomarkers for malignant pleural mesothelioma: current status
Future research efforts should focus on biomarkers predictive of the efficacy and toxicity of standard chemotherapy. Translational research should be systematically incorporated into the design of clinical trials assessing new targeted agents in MPM.
December 2nd, 2008. Monitoring of Chemotherapy Response in Malignant Pleural Mesothelioma Using Fluorodeoxyglucose Positron Emission Tomography
The tumor lesion exhibited shrinkage on CT and a decrease in the standardized uptake value (SUV) max after the first course of chemotherapy, but exhibited size enlargement and an increase in SUV max after the second course of chemotherapy. These findings suggest that results of quantification of metabolic response by FDG-PET are related to the objective response as determined by CT in patients with MPM.
Posted in CT or CAT scan, Case Study, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Full Archive, PET Scan, Pleural, Staging, Treatment, Type of Assessment:, Type of Mesothelioma: | 1 Comment »
November 26th, 2008. Malignant pleural mesothelioma: biology and diagnosis
Despite sometimes a good sensitivity, other potential markers as osteopontin are of little interest for MPM diagnosis because of a low specificity. In conclusion, the present data do not justify the use of biology for MPM diagnosis in routine yet but rather suggest a need for a continuing evaluation of soluble mesothelin in clinical studies and the search for other potential tumor markers.
November 26th, 2008. Mesothelioma: treatment
There are few active cytotoxic drugs in this disease. Currently, based on two randomised trials, the most efficacious chemotherapy regimen consists in a combination of cisplatin and an antifolate agent, pemetrexed or raltitrexed.
Posted in Chemotherapy, Cisplatin (Platinol ®), Full Archive, Pemetrexed (Alimta), Pleural, Pleurectomy/decortication, Pneumonectomy, Radiation, Raltitrexed (Tomudex), Surgery, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 21st, 2008. Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy
Not all linear accelerators can deliver large-field MLC-based IMRT, but most can deliver a maximum conformal field of 40 x 40 cm. It is possible and reasonable to deliver IMRT with compensators for fields this size with most conventional linear accelerators.
November 14th, 2008. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia
No difference is seen combining platinum analogs with gemcitabine or pemetrexed. Platinum-based doublets might represent a therapeutic ceiling for cytotoxic chemotherapy in MPM.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Pleural, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 11th, 2008. Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma
To show the specific effect of viral receptors knockdown experiments with siRNA for TLR3, RIG-I and MDA5 were performed. This finding of viral induced mesothelial VEGF synthesis may indicate a novel link between viral infections and formation of pleural effusions and progression of malignant mesothelioma.
November 8th, 2008. Effective chemotherapy based on a chemosensitivity test for malignant pleural mesothelioma
Numerous chemotherapeutic agents have been tested in many clinical trials, but the response rate does not exceed 20% for most of the investigated regimens. Here we report a case of MPM in which the chemotherapy based on the chemosensitivity test was very effective on palliation with stable disease for a long time.
November 8th, 2008. Transudates in Malignancy: Still a Role for Pleural Fluid
Conclusions: Cytological examination of pleural fluid in patients with unexplained transudative effusion is essential to rule out malignant processes.
November 5th, 2008. Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome
The patient was treated with immunoglobulin and prednisolone, and this resulted in subjective, objective, and paraclinical improvement of the symptoms. We therefore suggest that polyneuropathy is a possible paraneoplastic syndrome in MPM.
November 1st, 2008. Genomic events associated with progression of pleural malignant mesothelioma
Imbalances seen by ROMA were confirmed by Affymetrix genome analysis in a subset of samples. © 2008 Wiley-Liss, Inc.
October 31st, 2008. Diffuse malignant pleural mesothelioma: A multi-institutional clinicopathological study
Conclusions: The definitive diagnosis of early MPM is difficult, but establishing the best diagnostic modality would improve survival rates, since radical surgery is likely to be effective for resectable disease.
October 22nd, 2008. A case of non-tuberculous mycobacteriosis with pleurisy with a past history of dense exposure to environmental asbestos
A final diagnosis of NTM was confirmed via open biopsy of the lung. Our case suggests that in addition to tuberculosis, NTM should be taken into consideration as a complication of silicosis.
October 18th, 2008. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: A realistic treatment option?
Conclusion: The combination of carboplatin and pemetrexed may be a viable option in the treatment of malignant pleural mesothelioma.
Posted in Carboplatin, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Pemetrexed (Alimta), Pleural, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 18th, 2008. Expression and Regulation of Epithelial Na+ Channels by Nucleotides in Pleural Mesothelial Cells
Furthermore, we found that both forskolin and cGMP increased the short-circuit currents in mouse pleural tissues. Taken together, our data demonstrate that the ENaC channels are biochemically and functionally expressed in human pleural mesothelial cells, and can be up-regulated by cAMP and cGMP.
October 16th, 2008. Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy
Postoperative treatment was associated with DSS and with recurrence-free survival. Our study confirms that in many cases, final histopathologic typing of MPM is influenced by complete surgical resection and that initial biopsy should be carefully weighed in the treatment stratification.
October 8th, 2008. Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma
04). These results suggest that NAT2 polymorphisms do not exert a strong effect on individual susceptibility to MM.
October 3rd, 2008. Transesophageal Endoscopic Ultrasound with Fine Needle Aspiration in the Preoperative Staging of Malignant Pleural Mesothelioma
Conclusions: EUS-FNA is feasible and sensitive for MLN staging in patients with MPM who are candidate for multimodality treatment. These data warrant further evaluation.
September 23rd, 2008. Pleural fluid findings as prognostic factors for malignant pleural mesothelioma
However, none of these variables emerged as statistically significant from the multivariate Cox model. In conclusion, our results showed that there is an inverse correlation between the intensity of inflammation and survival.
September 23rd, 2008. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system
Conclusion: This study confirms a preferential pattern of drainage of malignant pleural mesothelioma to N2 rather than N1 lymph nodes, but suggests that N1 only nodal involvement should be classified as lower stage disease. Multiple N2 nodal site involvement could potentially be classified as higher stage disease than single station N2. Our results emphasize the need for larger, confirmatory multicenter studies that could lead to revision of the current staging system.
Posted in Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Staging, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
|
|  |
